Barclays’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Barclays’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-142,257	Closed	-$949K	–	5407
2023 Q3	$949K	Buy	142,257 +27,030	+23%	+$225K	﹤0.01%	2369
2023 Q2	$1.04M	Buy	115,227 +14,269	+14%	+$126K	﹤0.01%	2276
2023 Q1	$734K	Sell	100,958 -77,540	-43%	-$575K	﹤0.01%	2973
2022 Q4	$1.3M	Buy	178,498 +83,695	+88%	+$621K	﹤0.01%	2584
2022 Q3	$733K	Buy	94,803 +77,674	+453%	+$659K	﹤0.01%	2444
2022 Q2	$116K	Buy	17,129 +3,551	+26%	+$27.2K	﹤0.01%	3708
2022 Q1	$108K	Buy	+13,578	New	+$86.2K	﹤0.01%	3744

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Barclays's PNT Position: Q4 2023 in Review

Barclays sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 142,257 shares — an estimated $949K sold.

Barclays first reported a position in PNT in Q1 2022 and held it in 7 quarters. The position peaked at $1.3M in Q4 2022. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

Barclays reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Barclays sold 142,257 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $949K.
Barclays first reported a position in POINT Biopharma Global Inc. Common Stock in Q1 2022 and held it in 7 quarters.
Barclays's POINT Biopharma Global Inc. Common Stock position peaked at $1.3M in Q4 2022.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.